

Vito Di Marco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/668524/publications.pdf>

Version: 2024-02-01

169
papers

8,600
citations

34100

52
h-index

49904

87
g-index

170
all docs

170
docs citations

170
times ranked

9168
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. <i>Hepatology</i> , 2015, 61, 506-514. | 7.3 | 424 |
| 2 | Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet, The</i> , 2018, 391, 2417-2429. | 13.7 | 345 |
| 3 | Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4. | 1.3 | 291 |
| 4 | Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. <i>Hepatology</i> , 2004, 40, 883-891. | 7.3 | 237 |
| 5 | The long-term course of chronic hepatitis B. <i>Hepatology</i> , 1999, 30, 257-264. | 7.3 | 199 |
| 6 | Prophylaxis and treatment of hepatitis B in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2007, 39, 397-408. | 0.9 | 197 |
| 7 | The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2015, 62, 1101-1110. | 7.3 | 183 |
| 8 | Comparison of Transient Elastography and Acoustic Radiation Force Impulse for Non-Invasive Staging of Liver Fibrosis in Patients With Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2011, 106, 2112-2120. | 0.4 | 177 |
| 9 | Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. <i>Hepatology</i> , 2017, 65, 1145-1155. | 7.3 | 177 |
| 10 | Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2006, 43, 64-71. | 7.3 | 163 |
| 11 | Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. <i>Journal of Hepatology</i> , 2015, 62, 928-933. | 3.7 | 162 |
| 12 | SAFE biopsy: A validated method for large-scale staging of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2009, 49, 1821-1827. | 7.3 | 151 |
| 13 | Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1604-1611.e1. | 4.4 | 146 |
| 14 | Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273. | 3.7 | 138 |
| 15 | Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <sc>NAFLD</sc>. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 617-627. | 3.7 | 134 |
| 16 | Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. <i>Gastroenterology</i> , 2016, 151, 130-139.e2. | 1.3 | 130 |
| 17 | Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 1350-1360. | 3.7 | 126 |
| 18 | Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 757-766. | 3.7 | 125 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 688-695. | 3.7 | 124 |
| 20 | The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2015, 35, 1566-1573. | 3.9 | 116 |
| 21 | Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323. | 7.3 | 113 |
| 22 | Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 878-885. | 3.7 | 113 |
| 23 | Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2014, 9, e87523. | 2.5 | 112 |
| 24 | The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1202-1216. | 3.7 | 111 |
| 25 | Risk Factors and Outcome among a Large Patient Cohort with Community-Acquired Acute Hepatitis C in Italy. <i>Clinical Infectious Diseases</i> , 2006, 43, 1154-1159. | 5.8 | 108 |
| 26 | MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 682-690. | 3.7 | 106 |
| 27 | Randomised study comparing 48 and 96 weeks peginterferon \pm 2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298. | 12.1 | 105 |
| 28 | Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3. | 4.4 | 102 |
| 29 | Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005, 42, 535-540. | 3.7 | 101 |
| 30 | Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24. | 3.7 | 98 |
| 31 | Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. <i>Hepatology</i> , 2012, 56, 850-860. | 7.3 | 97 |
| 32 | Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 238-247. | 3.7 | 97 |
| 33 | Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: A randomized controlled trial. <i>Journal of Hepatology</i> , 2007, 47, 484-491. | 3.7 | 96 |
| 34 | Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. <i>Hepatology</i> , 2010, 52, 1543-1552. | 7.3 | 95 |
| 35 | Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. <i>Hepatology</i> , 1994, 19, 820-8. | 7.3 | 94 |
| 36 | Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial. <i>Journal of Hepatology</i> , 2004, 41, 474-481. | 3.7 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 867-874. | 2.0 | 91 |
| 38 | Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. <i>Blood</i> , 2010, 116, 2875-2883. | 1.4 | 79 |
| 39 | Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study. <i>Atherosclerosis</i> , 2020, 296, 40-47. | 0.8 | 78 |
| 40 | Long-term course of interferon-treated chronic hepatitis C. <i>Journal of Hepatology</i> , 1998, 28, 531-537. | 3.7 | 77 |
| 41 | Interferon lambda 4 rs368234815 TT>ÎG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2017, 66, 1885-1893. | 7.3 | 75 |
| 42 | Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. <i>Liver International</i> , 2018, 38, 2060-2068. | 3.9 | 72 |
| 43 | Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 523-529. | 3.7 | 67 |
| 44 | Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study. <i>Hepatology</i> , 2017, 66, 736-745. | 7.3 | 67 |
| 45 | Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2012, 4, 256. | 2.0 | 67 |
| 46 | The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1181-1191. | 3.7 | 66 |
| 47 | Anti-Tissue Transglutaminase Antibodies in Patients with Abnormal Liver Tests: Is It Always Coeliac Disease?. <i>American Journal of Gastroenterology</i> , 2005, 100, 2472-2477. | 0.4 | 65 |
| 48 | Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009, 49, 195-203. | 7.3 | 65 |
| 49 | PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089. | 2.5 | 59 |
| 50 | Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2408-2416. | 4.4 | 58 |
| 51 | Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. <i>Hepatology</i> , 2008, 48, 28-37. | 7.3 | 55 |
| 52 | Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2009, 14, 649-654. | 1.0 | 53 |
| 53 | Combined treatment of relapse of chronic hepatitis C with high-dose Î±2b interferon plus ribavirin for 6 or 12 months. <i>Journal of Hepatology</i> , 2000, 33, 456-462. | 3.7 | 51 |
| 54 | Oral pathology in untreated coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 1529-1536. | 3.7 | 50 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. <i>Haematologica</i> , 2008, 93, 1243-1246. | 3.5 | 50 |
| 56 | Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 196-204. | 3.7 | 50 |
| 57 | Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) – lack of interference by iron deposition. <i>British Journal of Haematology</i> , 2010, 148, 476-479. | 2.5 | 49 |
| 58 | Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 310-317. | 0.9 | 47 |
| 59 | IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. <i>Haematologica</i> , 2012, 97, 679-686. | 3.5 | 46 |
| 60 | Fibronectin Type III Domain-Containing Protein 5 rs3480 A&G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2660-2669. | 3.6 | 42 |
| 61 | Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies. <i>American Journal of Hematology</i> , 2017, 92, 1349-1355. | 4.1 | 42 |
| 62 | Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 92-104. | 3.7 | 41 |
| 63 | Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2345-2353. | 2.6 | 40 |
| 64 | HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. <i>Journal of Hepatology</i> , 2004, 40, 831-836. | 3.7 | 39 |
| 65 | Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. <i>Journal of Hepatology</i> , 2004, 40, 478-483. | 3.7 | 38 |
| 66 | On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349. | 3.7 | 38 |
| 67 | HCV viraemia is more important than genotype as a predictor of response to interferon in sicily (Southern Italy). <i>Journal of Hepatology</i> , 1996, 25, 583-590. | 3.7 | 37 |
| 68 | Hepatocellular Carcinoma Presenting at Contrast-Enhanced Multi-Detector-Row Computed Tomography or Gadolinium-Enhanced Magnetic Resonance Imaging as a Small ($\leq 2\text{ cm}$), Indeterminate Nodule. <i>Journal of Computer Assisted Tomography</i> , 2012, 36, 20-25. | 0.9 | 34 |
| 69 | Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. <i>Liver International</i> , 2017, 37, 1526-1534. | 3.9 | 34 |
| 70 | Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176. | 3.7 | 33 |
| 71 | Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. <i>Journal of Medical Virology</i> , 2003, 70, 581-587. | 5.0 | 32 |
| 72 | Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2132. | 3.3 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. <i>Digestive and Liver Disease</i> , 2010, 42, 585-592. | 0.9 | 30 |
| 74 | HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 312-321. | 4.4 | 30 |
| 75 | Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: A prospective study. <i>Digestive and Liver Disease</i> , 2008, 40, 684-689. | 0.9 | 29 |
| 76 | Treatment of chronic hepatitis B: Update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011, 43, 259-265. | 0.9 | 29 |
| 77 | Vitamin D Levels and IL28B Polymorphisms are Related to Rapid Virological Response to Standard of Care in Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2012, 17, 823-831. | 1.0 | 29 |
| 78 | HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years. <i>Journal of Hepatology</i> , 2012, 56, 1254-1258. | 3.7 | 29 |
| 79 | Serum γ -glutamyl Transferase Levels, Insulin Resistance and Liver Fibrosis in Patients with Chronic Liver Diseases. <i>PLoS ONE</i> , 2012, 7, e51165. | 2.5 | 29 |
| 80 | Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response. <i>PLoS ONE</i> , 2013, 8, e70016. | 2.5 | 29 |
| 81 | First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials. <i>Liver Cancer</i> , 2022, 11, 75-84. | 7.7 | 29 |
| 82 | Smouldering hepatitis B virus replication in patients with chronic liver disease and hepatitis delta virus superinfection. <i>Journal of Hepatology</i> , 1991, 12, 64-69. | 3.7 | 28 |
| 83 | Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. <i>Journal of Viral Hepatitis</i> , 2009, 17, 469-74. | 2.0 | 28 |
| 84 | Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Na ⁺ ve Patients With Primary Biliary Cholangitis: A Dual Cut-off Approach. <i>Hepatology</i> , 2021, 74, 1496-1508. | 7.3 | 28 |
| 85 | High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. <i>Digestive and Liver Disease</i> , 2011, 43, 404-410. | 0.9 | 27 |
| 86 | Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. <i>Gut</i> , 2002, 51, 864-869. | 12.1 | 26 |
| 87 | High efficacy of direct-acting antiviral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1705-1712. | 3.7 | 26 |
| 88 | Identification of Na ⁺ ve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. <i>Journal of Hepatology</i> , 2014, 60, 16-21. | 3.7 | 25 |
| 89 | Survival and causes of death in 2,033 patients with non-transfusion-dependent β -thalassemia. <i>Haematologica</i> , 2021, 106, 2489-2492. | 3.5 | 25 |
| 90 | Transfusion-associated chronic hepatitis C: Alpha-n1 interferon for 6 vs. 12 months. <i>Journal of Hepatology</i> , 1996, 24, 539-546. | 3.7 | 24 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. <i>Digestive and Liver Disease</i> , 2011, 43, 875-80. | 0.9 | 23 |
| 92 | Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <i>Digestive and Liver Disease</i> , 2005, 37, 882-885. | 0.9 | 22 |
| 93 | Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 603-613. | 3.7 | 22 |
| 94 | Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. <i>Analytical Cellular Pathology</i> , 2015, 2015, 1-7. | 1.4 | 22 |
| 95 | A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C. , 1997, 51, 17-24. | | 21 |
| 96 | Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?. <i>Liver International</i> , 2009, 29, 1171-1177. | 3.9 | 21 |
| 97 | Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2008, 15, 523-530. | 2.0 | 20 |
| 98 | TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. <i>Journal of Viral Hepatitis</i> , 2011, 18, e372-80. | 2.0 | 20 |
| 99 | Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 477-486. | 3.7 | 20 |
| 100 | Targeted Therapies in Hepatocellular Carcinoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 966-974. | 2.4 | 19 |
| 101 | Risk of mortality from anemia and iron overload in nontransfusionâ€dependent Î²â€thalassemia. <i>American Journal of Hematology</i> , 2022, 97, . | 4.1 | 19 |
| 102 | <scp>PNPLA</scp> rs738409 1748M is associated with steatohepatitis in 434 nonâ€obese subjects with hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 939-948. | 3.7 | 18 |
| 103 | Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis. <i>Liver International</i> , 2020, 40, 2820-2827. | 3.9 | 17 |
| 104 | Detection of hepatitis delta virus RNA in chronic liver disease. <i>Journal of Hepatology</i> , 1989, 9, 23-28. | 3.7 | 16 |
| 105 | Long-term evolution of chronic delta hepatitis in children. <i>Journal of Pediatrics</i> , 1993, 122, 736-738. | 1.8 | 16 |
| 106 | Alpha interferon treatment of chronic hepatitis C in beta-thalassaemia.. <i>Gut</i> , 1993, 34, S142-S143. | 12.1 | 16 |
| 107 | Role of ILâ€28B and inosine triphosphatase polymorphisms in efficacy and safety of Pegâ€interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. <i>Journal of Viral Hepatitis</i> , 2013, 20, 113-121. | 2.0 | 16 |
| 108 | Oral mucosa of coeliac disease patients produces antiendomysial and antitransglutaminase antibodies: the diagnostic usefulness of an <i>in vitro</i> culture system. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1471-1477. | 3.7 | 15 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 174-182. | 2.0 | 15 |
| 110 | rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. <i>Liver International</i> , 2016, 36, 198-204. | 3.9 | 15 |
| 111 | Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1013-1019. | 2.3 | 14 |
| 112 | Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction. <i>Journal of Viral Hepatitis</i> , 2002, 9, 354-359. | 2.0 | 14 |
| 113 | Hepatitis E virus infection as a cause of acute hepatitis in Southern Italy. <i>Digestive and Liver Disease</i> , 2011, 43, 996-1000. | 0.9 | 14 |
| 114 | Hepatitis C: Standard of Treatment and What to Do for Global Elimination. <i>Viruses</i> , 2022, 14, 505. | 3.3 | 14 |
| 115 | Parvovirus B19 and cryptogenic chronic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 375-376. | 3.7 | 13 |
| 116 | Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , 2012, 23, e124-e127. | 2.2 | 13 |
| 117 | Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 878-884.e1. | 4.4 | 13 |
| 118 | NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. <i>Cells</i> , 2019, 8, 666. | 4.1 | 13 |
| 119 | Current and forthcoming perspectives in linkage to care of hepatitis C virus infection: Assessment of an Italian focus group. <i>Digestive and Liver Disease</i> , 2019, 51, 915-921. | 0.9 | 13 |
| 120 | Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2012, 19, 465-472. | 2.0 | 12 |
| 121 | Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance. <i>Hepatitis Monthly</i> , 2013, 13, e7176. | 0.2 | 12 |
| 122 | Who is more likely to respond to dual treatment with pegylated interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. <i>Journal of Viral Hepatitis</i> , 2013, 20, 790-800. | 2.0 | 11 |
| 123 | Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?. <i>Digestive and Liver Disease</i> , 2016, 48, 650-655. | 0.9 | 11 |
| 124 | Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199. | 2.0 | 11 |
| 125 | Liver stiffness quantification in biopsy-proven nonalcoholic fatty liver disease patients using shear wave elastography in comparison with transient elastography. <i>Ultrasonography</i> , 2021, 40, 407-416. | 2.3 | 11 |
| 126 | Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. <i>Kidney International</i> , 2006, 70, 1187-1188. | 5.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Perception of the Role of Food and Dietary Modifications in Patients with Inflammatory Bowel Disease: Impact on Lifestyle. <i>Nutrients</i> , 2021, 13, 759. | 4.1 | 10 |
| 128 | PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981. | 4.4 | 10 |
| 129 | Chronic hepatitis B: who to treat and which choice of treatment?. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 281-291. | 4.4 | 9 |
| 130 | Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , 2011, 60, 1023-1023. | 12.1 | 9 |
| 131 | HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome. <i>Hepatology International</i> , 2015, 9, 52-57. | 4.2 | 9 |
| 132 | Effectiveness of a screening program for HBV, HCV, and HIV infections in African migrants to Sicily. <i>Digestive and Liver Disease</i> , 2022, 54, 800-804. | 0.9 | 9 |
| 133 | Phylogenetic analysis of isolates from new cases of HBV infection in Southern Italy. <i>Infection, Genetics and Evolution</i> , 2012, 12, 1591-1596. | 2.3 | 8 |
| 134 | An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 818-825. | 0.9 | 8 |
| 135 | Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. <i>Pathobiology</i> , 2015, 82, 48-52. | 3.8 | 8 |
| 136 | Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 117-128. | 4.4 | 8 |
| 137 | Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence. <i>Annals of Hepatology</i> , 2021, , 100568. | 1.5 | 8 |
| 138 | Treatment with interferon alfa-2b of chronic HDV hepatitis in children. <i>Journal of Hepatology</i> , 1990, 11, S175. | 3.7 | 7 |
| 139 | High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 953-958. | 3.7 | 7 |
| 140 | Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay. <i>Journal of Viral Hepatitis</i> , 2007, 15, 070901052026012-??? | 2.0 | 7 |
| 141 | A complication risk score to evaluate clinical severity of thalassaemia syndromes. <i>British Journal of Haematology</i> , 2021, 192, 626-633. | 2.5 | 7 |
| 142 | Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. <i>Journal of Oral Pathology and Medicine</i> , 2009, 38, 34-41. | 2.7 | 6 |
| 143 | Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FIS (HEpatitis C Virus Fingerstick) Tj ETQq1_1 0.784314 rgBT / D | 3.9 | 6 |
| 144 | Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). <i>Digestive and Liver Disease</i> , 2021, 53, 1301-1307. | 0.9 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Interplay between nonalcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396. | 2.8 | 6 |
| 146 | rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719. | 3.9 | 6 |
| 147 | A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044. | 4.3 | 6 |
| 148 | Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease?. <i>Digestive and Liver Disease</i> , 2002, 34, 53-58. | 0.9 | 5 |
| 149 | Congenital Hepatic Fibrosis. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 567-568. | 0.6 | 5 |
| 150 | HCV Clearance Among Hemophiliacs and Beta-Thalasseemics. <i>Gastroenterology</i> , 2007, 132, 1634. | 1.3 | 5 |
| 151 | Chronic hepatitis C in children is a mild and curable liver disease. <i>Digestive and Liver Disease</i> , 2011, 43, 266-267. | 0.9 | 5 |
| 152 | Impact of HBV genotypes A and D genetic variability on infection evolution. <i>Infection, Genetics and Evolution</i> , 2015, 33, 281-287. | 2.3 | 5 |
| 153 | Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECA Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255. | 0.4 | 5 |
| 154 | HCV-1b intra-subtype variability: Impact on genetic barrier to protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2014, 23, 80-85. | 2.3 | 4 |
| 155 | Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients. <i>Infection</i> , 2019, 47, 409-415. | 4.7 | 4 |
| 156 | Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy. <i>Journal of Hospital Infection</i> , 2021, 115, 51-58. | 2.9 | 4 |
| 157 | A cholestatic pattern predicts major liver-related outcomes in patients with nonalcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048. | 3.9 | 4 |
| 158 | Adefovir for lamivudine resistant HBV: More than meets the eye. <i>Journal of Hepatology</i> , 2007, 47, 618-619. | 3.7 | 3 |
| 159 | Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals. <i>Liver International</i> , 2021, 41, 2179-2188. | 3.9 | 3 |
| 160 | Random Forest Clustering Identifies Three Subgroups of Î²-Thalassemia with Distinct Clinical Severity. <i>Thalassemia Reports</i> , 2022, 12, 14-23. | 0.5 | 3 |
| 161 | Sicily Network for Liver Cancer: A Multidisciplinary Network Model for the Management of Primary Liver Tumors. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2020, 30, 1048-1053. | 1.0 | 2 |
| 162 | Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021, 67, 254-263. | 0.5 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Hepatitis C virus replication in chronic liver disease. <i>Journal of Hepatology</i> , 1991, 13, S40-S41. | 3.7 | 1 |
| 164 | A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , 2003, 35, 372-373. | 0.9 | 1 |
| 165 | Chronic hepatitis B: Do we know everything or is there still something to learn?. <i>Digestive and Liver Disease Supplements</i> , 2009, 3, 61-66. | 0.2 | 1 |
| 166 | Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy. <i>Liver International</i> , 2020, 40, 530-538. | 3.9 | 1 |
| 167 | Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3477-3480. | 2.3 | 1 |
| 168 | Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2022, 54, 1117-1121. | 0.9 | 1 |
| 169 | Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals. <i>Diagnostics</i> , 2022, 12, 1187. | 2.6 | 0 |